Cochlear (ASX:COH) Shares Climb As Margins Crumple Under One Off Losses

Cochlear stock has been on a tear, up about 49% over the past three months to A$141.20, yet the latest result landed with a thud on the income line. The headline is simple: revenue held above A$2.3b, but a large one off loss over the past year dragged reported earnings into the red and compressed net margins to 6.3% from 16.6%.

Short term traders are reacting to that squeeze. Long term holders are weighing a P/E of 62.7x against earnings forecasts that still point to faster profit growth than the wider Australian market.

Love Cochlear's revenue resilience but concerned about rich valuations and earnings pressure from one off losses? Take a look at our curated list of 10 resilient stocks with low risk scores for alternatives that pair quality fundamentals with more moderate valuation profiles.

FY 2026 Earnings Summary

• Revenue (FY 2026 vs FY 2025 PCP): A$2,347.6m vs. A$2,343.1m (largely steady on a full year view)
• Net Income from Continuing Operations (FY 2026 vs FY 2025 PCP): A$147.3m vs. A$388.9m (sharp decline in reported profit)
• Basic EPS (Earnings Per Share) (FY 2026 vs FY 2025 PCP): A$2.252 vs. A$5.943021 (earnings per share fell materially year on year)
• Net Profit Margin (Trailing 12 Months vs Prior Year): 6.3% vs. 16.6% (margin compressed, reflecting weaker profitability and one off loss impact)

Prefer clear charts instead of another wall of profit and margin figures? View Cochlear's full financial picture, including a clear view of its earnings trend, in the company report for Cochlear.

Cochlear’s Growth Story Put To The Test

Bulls argue Cochlear can grow by lifting revenue per implant, scaling services and using Nexa and Osia 3 to keep its product edge. The FY26 numbers partially back that up. Nexa now represents more than 95% of implant sales in developed markets and carries around a 3% average price improvement there. That is a clear milestone for the higher revenue per unit story.

Volume and mix tell a tougher story. Global cochlear implant systems rose 5% by units, but revenue in constant currency stayed flat as China’s volume based pricing and a tilt to lower tier products offset Nexa gains. The services business grew 6% in constant currency, with 50,000 upgrades supporting the recurring revenue narrative, and Osia 3 clearance gives that upgrade engine more product depth. Overall, the bullish thesis on product and services momentum is tracking, but pricing power outside developed markets is still unproven.

Compare Cochlear’s progress on Nexa, Osia 3 and recurring services revenue with what the street is actually pricing in. See the consensus price target analysis for Cochlear to check whether analyst targets line up with this bullish thesis or tell a different story.

Cochlear Bear Case Finds Support In Margin Reset

The bearish narrative argues that Cochlear’s near term earnings are capped by weaker implant demand, higher Nexa launch costs and mix pressure from lower priced markets. The FY26 result largely validates those concerns. Global cochlear implant units rose 5% yet revenue in constant currency stayed flat as China’s volume based pricing and reimbursement changes pushed mix toward lower tier products. Gross margin fell about 3 percentage points to roughly 71% and management now guides only 70 to 71% for FY27, which shows limited near term relief from the Nexa manufacturing learning curve and China headwinds.

Bears also flagged rising operating costs and restructuring drag. Underlying net profit of about US$322m sits below the original FY26 plan and required a guidance cut, while reported profit absorbed roughly US$69m of restructuring and short term incentive charges. Cost out programs and better cash flow help, but the key milestones on margin recovery were missed rather than cleared.

After a year where profit margins reset from 16.6% to 6.3% and one off charges hit earnings quality, it is fair to ask whether this is just a short term wobble or a sign of deeper structural issues inside Cochlear. Review the independent risk analysis for Cochlear which shows 3 important warning signs

Stay Ahead Of Your Next Move

If Cochlear’s strong share price run and margin reset have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more comfortable entry point. Once you own Cochlear or other stocks, use the Portfolio Command Center to cut through market noise and focus on the most important updates on earnings, valuation and risks. Round out your process by tapping into crowd wisdom through the Community and see how other investors are thinking about the same signals. By spotting potential catalysts and red flags early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Cochlear Stock

Fresh ideas move fast. By the time most investors spot a breakout, the best entry is gone and momentum is already flying. Scan these under the radar lists and act now.

• Spot potential breakout yield opportunities before they are widely discussed by reviewing carefully filtered 4 dividend fortresses that aim to balance income strength with balance sheet resilience.
• Track where capital could be gathering early by checking hand picked 56 AI infrastructure stocks that support the hardware and networks behind rising AI demand while it still flies under most radars.
• Hunt for potential early leaders in electrification trends and grid upgrades by scanning curated 39 power grid technology and infrastructure stocks before the crowd fully prices in these themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com